title: [Comparison of lansoprazole (30 mg) and omeprazole (20 mg) in the treatment of duodenal ulcer. A multicenter double-blind comparative trial].
abstract: The efficacy of lansoprazole (30 mg/d) and omeprazole (20 mg/d) has been assessed in active duodenal ulcer disease in 144 patients included in a multicentric, randomized, double-blind trial. After two weeks, the healing rates were 74% and 58% in the lansoprazole and omeprazole groups, respectively (P = 0.049). After 4 weeks, the healing rates were 94% in each group (NS). The delay to pain relief was 2 days for lansoprazole and 3 days for omeprazole (NS). Minor side effects occurred in 12% of the lansoprazole treated patients and in 13% of the omeprazole treated patients. No severe adverse events were reported. A slight increase in serum gastrin level was observed, similar in both groups (+35 UI/L and +19 UI/L for lansoprazole and omeprazole respectively). This study confirms previous results concerning the efficacy of both treatments in duodenal ulcer disease. The statistical difference observed for healing rates after 2 weeks could correspond to a faster efficacy for lansoprazole (30 mg) than for omeprazole (20 mg).
authors.affiliation: Service de Gastroentérologie, Hôpital Broussais, Paris.
authors.forename: J P
authors.initials: JP
authors.lastname: Petite
authors.forename: J L
authors.initials: JL
authors.lastname: Slama
authors.forename: H
authors.initials: H
authors.lastname: Licht
authors.forename: M
authors.initials: M
authors.lastname: Lemerez
authors.forename: T
authors.initials: T
authors.lastname: Coste
authors.forename: J
authors.initials: J
authors.lastname: Andrieu
authors.forename: J C
authors.initials: JC
authors.lastname: Grimaud
authors.forename: H
authors.initials: H
authors.lastname: Julien
authors.forename: J
authors.initials: J
authors.lastname: Dupuis
authors.forename: V
authors.initials: V
authors.lastname: Sallerin
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000284:Administration, Oral; D000328:Adult; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D004381:Duodenal Ulcer / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D005260:Female; D005755:Gastrins / Q000032:analysis; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D010146:Pain / Q000188:drug therapy / Q000209:etiology
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D005755:Gastrins; D064747:Lansoprazole; D009853:Omeprazole
vernacular_title: Comparaison du lansoprazole (30 mg) et de l'oméprazole (20 mg) dans le traitement de l'ulcère duodénal. Essai thérapeutique multicentrique comparatif en double aveugle.